Drug Profile
Research programme: bispecific monoclonal antibodies - Amgen/Xencor
Alternative Names: XmAb bispecific x5; XmAb13551; XmAb14702; XmAb15426Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Amgen; Xencor
- Class Anti-inflammatories; Antineoplastics; Bispecific antibodies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Cancer in USA
- 28 Oct 2019 No recent reports of development identified for research development in Inflammation in USA
- 16 Sep 2015 Amgen and Xencor agree to co-develop and co-promote bispecific monoclonal antibodies in World for cancer and inflammation